Company intelligence / Profile preview

Juli Healthcare

Boston, United States

Ownership: Private
Development stage: Other

Overview

Juli has demonstrated efficacy through two large randomized controlled trials (RCTs). The asthma RCT is published in JMIR (Journal of Medical Internet Research) and the depression RCT is published in Sage journals, showing improved outcomes compared to active control apps[3]. The platform achieves 37.2% user retention after 30 days (industry average: 3.7%) with more than half of active users engaging at least twice per week[3][4].

Therapeutic areas: PsychiatryNeurologyPulmonology
Modalities: Non-pharmacological therapy (digital health platform)
Industry: Digital Health Medical Devices

Partnerships

Healthcare systems and providers (B2B model)

Beyond the preview

Go deeper on Juli Healthcare.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Juli Healthcare.

Explore the full profile